Published in Gene Therapy Weekly, May 24th, 2007
The vaccine trial, which is being conducted at the newly dedicated Johnny L. Cochran, Jr. Brain Tumor Center at Cedars-Sinai Medical Center in Los Angeles, is being funded by IMUC and is designed to evaluate safety/toxicity, feasibility and biological activity. The trial should also provide a preliminary indication of whether the vaccine is generating an immune response in patients, one of the necessary preconditions to the vaccine being effective. Approximately 30 patients are expected to be enrolled in the trial, which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.